CordenPharma invests €900m in peptide patform expansion

CordenPharma has announced its largest strategic investment to date with a committed spend of ~€900m over the next 3 years to grow its peptide technology platform.The production capacity expansions, covering both existing facilities and new constructions, will meet the pharmaceutical industry’s most stringent quality and technical standards for short and long peptide manufacturing, including BLA requirements.

The Colorado, US site’s expansion will target additional large-scale peptide manufacturing capacity to meet the increasing demand of GLP-1 peptides, resulting from multiple long-term manufacturing contracts of diabetes and obesity drug makers totaling ~€3bn, with potential upsides. In Europe, CordenPharma will construct a greenfield site for small to large-scale peptide development and manufacturing, integrated within its global facility network. As recently as September 2023, Cordenpharma upgraded the existing 10,000-liter reactor with a batch size of over 400 kg and an annual capacity of more than two tons of peptide and increased the downstream High-Pressure Liquid Chromatography (HPLC) purification capacity by 50%.

The company’s major expansion plans will act as the driving force behind the CDMO’s €1bn sales target for its Peptide Platform by 2028, reinforcing it as a market leader in the integrated supply of small to large-scale services from APIs to Drug Products for both injectable and oral peptides. In 2022, CordenPharma was acquired by the private equity specialist Astorg.

The CordenPharma Group is comprised of 11 facilities across Europe and North America. In the 2023 financial year, the organization generated sales of €880 mand had over 3,000 employees.